Were Analysts Bullish CymaBay Therapeutics, Inc. (NASDAQ:CBAY) This Week?

April 20, 2018 - By Richard Conner

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

Among 8 analysts covering CymaBay Therapeutics (NASDAQ:CBAY), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CymaBay Therapeutics had 16 analyst reports since October 25, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, March 21 by Oppenheimer. Leerink Swann maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, April 11 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, January 24 report. The firm has “Buy” rating given on Wednesday, January 10 by Oppenheimer. As per Wednesday, January 31, the company rating was maintained by Piper Jaffray. The company was maintained on Friday, March 16 by SunTrust. The rating was maintained by Piper Jaffray with “Buy” on Thursday, March 15. The firm has “Buy” rating given on Monday, April 16 by Roth Capital. H.C. Wainwright initiated the stock with “Buy” rating in Wednesday, March 28 report. Leerink Swann maintained the stock with “Buy” rating in Tuesday, November 28 report. Below is a list of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) latest ratings and price target changes.

16/04/2018 Broker: Roth Capital Rating: Buy New Target: $27.0000 Maintain
11/04/2018 Broker: Leerink Swann Rating: Buy New Target: $20.0000 Maintain
11/04/2018 Broker: Evercore Rating: Buy
28/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Initiate
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $16.0000 Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: SunTrust Rating: Buy New Target: $19.0 Maintain
16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $16.0 Maintain
13/02/2018 Broker: Evercore Rating: Outperform Initiates Coverage On

The stock increased 0.26% or $0.035 during the last trading session, reaching $13.355. About 476,583 shares traded. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 197.77% since April 20, 2017 and is uptrending. It has outperformed by 186.22% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $781.29 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.